MedTrace Logo

Treatment of Chronic Mountain Sickness

NCT04251364 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-31

No results posted yet for this study

Summary

This study aims to assess the effect of two drugs for the treatment of chronic mountain sickness in highlanders.

Conditions

  • Hypoxia, Altitude

Interventions

DRUG

Acetazolamide

Daily acetazolamide pill intake

DRUG

Atorvastatin

Daily atorvastatin pill intake

DRUG

Placebo oral tablet

Daily placebo pill intake

Sponsors & Collaborators

  • Centre d'Expertise sur l'Altitude EXALT

    lead OTHER

Principal Investigators

  • Samuel Verges, PhD · EXAL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-15
Primary Completion
2021-10-30
Completion
2021-12-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251364 on ClinicalTrials.gov